



LANTHEUS HOLDINGS, INC.

Science and Technology Committee Charter

This Science and Technology Committee Charter (this “*Charter*”) was adopted by the Board of Directors (the “*Board*”) of Lantheus Holdings, Inc. (the “*Company*”) on April 27, 2023.

This Charter is intended as a component of the flexible governance framework within which the Board, assisted by its committees, directs the affairs of the Company. While it should be interpreted in the context of all applicable laws, regulations and listing requirements, as well as in the context of the Company’s Certificate of Incorporation and Bylaws, it is not intended to establish by its own force any legally binding obligations.

1. PURPOSES

In order to assist the Board in fulfilling its responsibilities, the Science and Technology Committee (the “*Committee*”) will advise on:

- the direction of, and investment in, the Company’s new science and technology initiatives, including without limitation with respect to its diagnostic and therapeutic development pipeline, approved product and device portfolio, pharma services, isotopes, digital solutions and business development activities; and
- scientific, technological, medical, regulatory, product safety, “good practice (GxP) compliance and intellectual property matters of importance to the Company’s research and development, clinical development, manufacturing process development, pipeline and portfolio management, and other programs and projects (collectively, the “*S&T Programs*”).

In discharging its role, the Committee is empowered to inquire into any matter it considers appropriate to carry out its responsibilities, with access to all books, records, facilities and personnel of the Company, and, subject to the direction of the Board, the Committee is authorized and delegated the authority to act on behalf of the Board with respect to any matter necessary or appropriate to accomplish its purposes. The Committee is empowered to retain outside science, technology, medical, regulatory, intellectual property and other advisors and consultants to assist it in carrying out its activities. The Company will provide adequate resources to support the Committee’s activities, including compensation of any advisor or consultant retained by the Committee.

2. COMMITTEE MEMBERSHIP

The Committee will consist of such number of members as determined by the Board from time to time. Except as otherwise directed by the Board, a director selected as a Committee member will continue to be a member for as long as he or she remains a director or until his or her earlier death, resignation or removal. Any member may be removed from the Committee by the Board, with or without cause, at any time. The Chairperson of the Committee will be appointed from among the Committee members by the Board, after taking into account the recommendation of the Nominating and Corporate Governance Committee of the Board, will serve at the pleasure of the Board, will preside at meetings of the Committee, and will have authority to convene meetings, set agendas for meetings and determine the Committee’s information needs, except as otherwise provided by action of the Committee. In the absence of the Chairperson at a duly convened meeting, the Committee will select a temporary substitute from among its members to serve as chairperson of the meeting.

3. COMMITTEE MEETINGS

The Committee will meet (i) on a regularly-scheduled basis at least four times per year and (ii) additionally as circumstances dictate.

Notice of meetings will be given to all Committee members, or may be waived, in the same manner as required for meetings of the Board. Meetings of the Committee may be held by means of telephone or video conference or other means of communications through which all persons participating in the meeting can hear each other. A majority of the members of the Committee will constitute a quorum for a meeting, and the affirmative vote of a majority of members present at a meeting at which a quorum is present will constitute the action of the Committee. The Committee may form, and delegate any of its responsibilities to, a subcommittee so long as that subcommittee is solely comprised of one or more members of the Committee. The Committee will otherwise establish its own rules of procedure. The Committee may also act by unanimous written consent of its members.

4. RESPONSIBILITIES

The following duties, responsibilities and functions are set forth only as a guide to fulfilling the Committee's purposes, with the understanding that the Committee may undertake other and different activities, and that the Committee's activities may diverge from those described below, as appropriate under the circumstances.

In such manner as the Committee determines is appropriate to fulfill its purposes, the Committee will:

- Advise on the scientific, technological, medical, regulatory, product safety, GxP compliance and intellectual property aspects of the Company's S&T Programs, including with respect to the Company's strategic process and material business development opportunities;
- anticipate, monitor and evaluate significant issues, developments and trends (and the associated risks and opportunities) in the areas of science, technology, medicine, regulation and intellectual property relevant to the Company's S&T Programs;
- advise on the Company's intellectual property portfolio and strategy, its regulatory strategy and its integrated intellectual property and regulatory strategy, including from the standpoints of exclusivity, infringement and misappropriation;
- assist the Board with its oversight responsibility for the Company's internal and external science and technology expertise and capabilities, including with respect to the effectiveness and quality of the advice, information and due diligence processes supporting corporate decision-making;
- assist management, where appropriate, in evaluating the scientific, technological, medical, regulatory and intellectual property aspects involved in potential collaborations, alliances, licenses, acquisitions and other similar projects;
- (i) review and discuss with management any significant risks or exposures and the Company's policies and processes with respect to enterprise risk assessment and enterprise risk management relating to (A) product safety matters, (B) GxP compliance matters and (C) intellectual property matters, (ii) assess the steps management has taken to monitor and control those risks, and (iii) oversee the Company's related legal and regulatory compliance;
- conduct a self-evaluation of the performance of the Committee from time to time as determined in the sole discretion of the Committee;
- report regularly to the Board on Committee findings and recommendations and any other matters the Committee deems appropriate or the Board requests, and maintain minutes or other records of Committee meetings and activities; and
- review and reassess the adequacy of this Charter annually, and recommend to the Board amendments to this Charter as the Committee deems appropriate.

* * *